Drugs in the Pipeline
Soligenix announced that the FDA has granted Orphan Drug Designation to OrbeShield (oral beclomethasone 17,21-dipropionate or oral BDP) for the prevention of death following a potentially lethal dose of total body irradiation (TBI) during or after a radiation disaster.
News
The FDA has approved the New Drug Application (NDA) for Emend (aprepitant; Merck) for oral suspension for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients aged ≥6 months old.
AAO-HNS 2021
Study authors conducted a prospective randomized trial to determine if there is a role for oral steroids in patients who have CRSsNP.
Drugs in the Pipeline
Soligenix announced today that the FDA has designated its OrbShield (oral beclomethasone 17, 21-dipropionate or oral BDP) development program for the treatment of Gastrointestinal Acute Radiation Syndrome (GI ARS), for Fast Track review.
News
The team found no significant differences between the three groups of children who received topical steroid, emollient, or placebo in terms of Patient Oriented Eczema Measure scores.
News
Taro Pharmaceuticals has received FDA approval for Flo-Pred (prednisolone acetate oral suspension), a prescription corticosteroid for the treatment of asthma, certain allergic and dermatologic conditions, and a variety of other indications.
Uncategorized
Both the 60- and 120-actuation sizes have been discontinued.
Slideshow
A white 24-year-old female presents with erythematous, papulopustular patches of skin in a muzzle-like distribution surrounding the mouth, chin, and glabellar region. Her history includes a variety of topical antibiotics that were previously successful with complete resolution; however, at present the lesions are persisting despite the treatment.
News
Under drug interactions, new clinical comments regarding concomitant systemic/inhaled/nasal/ophthalmic corticosteroids have been added.
News
Findings based on number of symptom-free days for daily versus as-needed treatment
